Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Shinyaku: Pharm. Sales Up 3.6% Driven by Mainstay Products
May 31, 2010
- Bayer Initiates PIII of Regorafenib in mCRC
May 31, 2010
- Kissei: Sales Down 3.7%, Off-Patent Products Struggle
May 31, 2010
- Sosei Initiates PIII for QVA149
May 31, 2010
- Medipal: Sales Up 3.3% to ¥2,546 Bil.
May 31, 2010
- 9-Valent HPV Vaccine under Development in Japan: Banyu
May 31, 2010
- Fully Explain Characteristics of Asthma to Patients to Improve Compliance: Prof. Ohta
May 31, 2010
- Alfresa HD: Sales Up 6.4% to ¥2,059.2 Bil.
May 31, 2010
- Roche, Biogen Idec Discontinue Development of Ocrelizumab for RA
May 31, 2010
- 2 Advanced Therapies Recommended for Combination with Insurance-Covered Therapies
May 31, 2010
- Suzuken: Operating Profits Down 14.5% Despite 4.9% Increase in Sales
May 31, 2010
- Insomnia Increases Risk of Diabetes: Prof. Watanabe
May 31, 2010
- Crestor Indicated in EU for Prevention of Major CV Events: AZ
May 31, 2010
- Toho HD: Sales Top \1 Trillion Benchmark
May 31, 2010
- Takeda President Yasuchika Hasegawa Elected JPMA President
May 31, 2010
- Settle Prices on a Product-by-Product Basis: Mr Matsutani
May 31, 2010
- JPMA Proposes Specific Measures for Growth Strategy
May 31, 2010
- Korosho Completes Hearings of Wholesalers on Changes in Business Practice
May 31, 2010
- MTPC: Pharma Sales Up 2.2% Driven by Remicade
May 24, 2010
- GSK's Ofatumumab Receives Conditional Approval in EU
May 24, 2010
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…